As Ocuphire Pharma Rally Gathers Steam Post-Results, What Did Investors Initially Miss?
After a Q4 beat garnered little immediate reaction, OCUP stock has now traded more than 40% higher Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its fourth-quarter and year-end financial results on March 30, indicating a successful year with significant clinical, regulatory, patent, and strategic partner milestones. Q1 2023 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you're ready to be matched with lo...